etanidazole has been researched along with Brain Neoplasms in 14 studies
Etanidazole: A nitroimidazole that sensitizes hypoxic tumor cells that are normally resistant to radiation therapy.
etanidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitro-1H-imidazol-1-yl)acetic acid with the amino group of ethanolamine. Used as a radiosensitising agent for hypoxic tumour cells.
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the maximum tolerable total dose (MTD) of etanidazole (ETA) when administered with external beam radiotherapy (XRT) and as a continuous infusion during stereotactic brachytherapy for patients with malignant glioma (anaplastic astrocytoma or glioblastoma multiforme or mixed cell tumors)." | 9.07 | A phase I study of etanidazole and radiotherapy in malignant glioma. ( Alexander, E; Black, PM; Coleman, CN; Loeffler, JS; Riese, NE; Wen, P, 1994) |
| "To report the survival results from a previous Phase I study of etanidazole (ETA) and radiotherapy in patients with glioblastoma multiforme (GBM n = 50) or anaplastic astrocytoma (AA n = 19) and examine survival according to age, Karnofsky performance status (KPS), and implant status." | 5.08 | Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma. ( Alexander, E; Black, PM; Chang, EL; Coleman, CN; Loeffler, JS; Riese, NE; Wen, PY, 1998) |
| "To determine the maximum tolerable total dose (MTD) of etanidazole (ETA) when administered with external beam radiotherapy (XRT) and as a continuous infusion during stereotactic brachytherapy for patients with malignant glioma (anaplastic astrocytoma or glioblastoma multiforme or mixed cell tumors)." | 5.07 | A phase I study of etanidazole and radiotherapy in malignant glioma. ( Alexander, E; Black, PM; Coleman, CN; Loeffler, JS; Riese, NE; Wen, P, 1994) |
| "Patients had primary or metastatic brain tumors and previously localized or whole brain irradiation." | 2.73 | A phase I-B trial of the radiosensitizer: etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02). ( Cmelak, AJ; Drzymala, RE; Loeffler, J; Shaw, E; Souhami, L; Wasserman, TH; Won, M, 2008) |
| "Tissues from six human brain tumors were assessed." | 1.35 | Imaging and analytical methods as applied to the evaluation of vasculature and hypoxia in human brain tumors. ( Dilling, T; Evans, SM; Hahn, SM; Jenkins, KW; Jenkins, WT; Judkins, A; Judy, KD; Koch, CJ; Schrlau, A, 2008) |
| "Human brain tumors are dominated by oxic to moderately hypoxic cells." | 1.32 | Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. ( Collins, R; Dunphy, I; Evans, SM; Geoerger, B; Hahn, SM; Jenkins, K; Jenkins, WT; Judkins, AR; Judy, KD; Koch, CJ; Nelson, PT; Phillips, P; Stevens, CW; Wileyto, EP, 2004) |
| "Etanidazole was developed as an oxygen-mimetic radiosensitizer less lipophilic than misonidazole." | 1.28 | Distribution of etanidazole into human brain tumors: implications for treating high grade gliomas. ( Alexander, E; Buswell, L; Coleman, CN; Hurwitz, SJ; Kramer, RA; Loeffler, JS; Neben, TY; Riese, N; Shargel, L, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Evans, SM | 5 |
| Jenkins, KW | 1 |
| Jenkins, WT | 3 |
| Dilling, T | 1 |
| Judy, KD | 4 |
| Schrlau, A | 1 |
| Judkins, A | 1 |
| Hahn, SM | 4 |
| Koch, CJ | 5 |
| Scheuermann, JS | 1 |
| Divgi, C | 1 |
| Kachur, AV | 1 |
| Freifelder, R | 1 |
| Reddin, JS | 1 |
| Karp, J | 1 |
| Stubbs, JB | 1 |
| Driesbaugh, J | 1 |
| Smith, D | 1 |
| Prendergast, S | 1 |
| Tan, WH | 2 |
| Wang, F | 1 |
| Lee, T | 2 |
| Wang, CH | 2 |
| Dunphy, I | 2 |
| Nelson, PT | 2 |
| Collins, R | 1 |
| Wileyto, EP | 1 |
| Jenkins, K | 2 |
| Stevens, CW | 1 |
| Judkins, AR | 1 |
| Phillips, P | 1 |
| Geoerger, B | 1 |
| Hwang, WT | 1 |
| Lustig, RA | 1 |
| Magarelli, DP | 1 |
| Collins, RA | 1 |
| Grady, MS | 1 |
| Vordermark, D | 1 |
| Drzymala, RE | 1 |
| Wasserman, TH | 1 |
| Won, M | 1 |
| Shaw, E | 1 |
| Cmelak, AJ | 1 |
| Loeffler, J | 1 |
| Souhami, L | 1 |
| Riese, NE | 2 |
| Loeffler, JS | 3 |
| Wen, P | 1 |
| Alexander, E | 3 |
| Black, PM | 2 |
| Coleman, CN | 3 |
| Chang, EL | 1 |
| Wen, PY | 1 |
| Hurwitz, SJ | 1 |
| Riese, N | 1 |
| Buswell, L | 1 |
| Neben, TY | 1 |
| Shargel, L | 1 |
| Kramer, RA | 1 |
| Wong, KH | 1 |
| Wallen, CA | 1 |
| Wheeler, KT | 1 |
| Newman, HF | 1 |
| Bleehen, NM | 1 |
| Ward, R | 1 |
| Workman, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer[NCT01881451] | 5 participants (Actual) | Observational | 2013-08-31 | Terminated (stopped due to Due to slow accrual and access to the study drug.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for etanidazole and Brain Neoplasms
| Article | Year |
|---|---|
Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma.
Topics: Biological Transport; Brain Neoplasms; Cell Hypoxia; Etanidazole; Female; Fluorine Radioisotopes; Gl | 2010 |
A phase I-B trial of the radiosensitizer: etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02).
Topics: Adult; Brain Neoplasms; Combined Modality Therapy; Etanidazole; Humans; Neoplasm Recurrence, Local; | 2008 |
A phase I study of etanidazole and radiotherapy in malignant glioma.
Topics: Adult; Aged; Brachytherapy; Brain Neoplasms; Etanidazole; Female; Glioma; Humans; Male; Middle Aged | 1994 |
Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brachytherapy; Brain Neoplasms; Etanidazole; Feasib | 1998 |
10 other studies available for etanidazole and Brain Neoplasms
| Article | Year |
|---|---|
Imaging and analytical methods as applied to the evaluation of vasculature and hypoxia in human brain tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Animals; Brain Neoplasms; Etanidazole; Gliob | 2008 |
In regard to Brown et al. (Int J Radiat Oncol Biol Phys 2010;78:323-327).
Topics: Brain Neoplasms; Cell Hypoxia; Etanidazole; Humans; Neoplasms; Radiation-Sensitizing Agents | 2011 |
Computer simulation of the delivery of etanidazole to brain tumor from PLGA wafers: comparison between linear and double burst release systems.
Topics: Animals; Brain Neoplasms; Computer Simulation; Drug Delivery Systems; Drug Implants; Etanidazole; Hu | 2003 |
Simulation of intratumoral release of Etanidazole: effects of the size of surgical opening.
Topics: Biological Availability; Brain Neoplasms; Computer Simulation; Drug Delivery Systems; Edema; Etanida | 2003 |
Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding.
Topics: Adult; Aged; Brain Neoplasms; Cell Hypoxia; Electrodes; Etanidazole; Humans; Hydrocarbons, Fluorinat | 2004 |
Hypoxia is important in the biology and aggression of human glial brain tumors.
Topics: Aged; Brain Neoplasms; Electrodes; Etanidazole; Glioma; Humans; Hydrocarbons, Fluorinated; Hypoxia; | 2004 |
Significance of hypoxia in malignant glioma. Re: Evans et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004;10:8177-84.
Topics: Antineoplastic Agents; Brain Neoplasms; Etanidazole; Glioma; Humans; Hydrocarbons, Fluorinated; Hypo | 2005 |
Distribution of etanidazole into human brain tumors: implications for treating high grade gliomas.
Topics: Brain Neoplasms; Combined Modality Therapy; Drug Evaluation; Etanidazole; Humans; Infusions, Intrave | 1992 |
2-Nitroimidazole potentiation of nitrosourea induced cytotoxicity in subcutaneous implants of rat 9L brain tumor cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 1991 |
Hypoxic cell radiosensitizers in the treatment of high grade gliomas: a new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Topics: Brain Neoplasms; Drug Therapy, Combination; Etanidazole; Glioblastoma; Humans; Nitroimidazoles; Radi | 1988 |